secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0000950170-24-029236
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar doses first patient in open-label extension study of nomlabofusp for Friedreich's ataxia
--------------------------------------------------------------------------------

- First patient dosed in OLE evaluating 25 mg daily subcutaneous nomlabofusp for Friedreich's ataxia.
- OLE to assess long-term safety, pharmacokinetics, and tissue frataxin levels; initial data expected Q4 2024.
- Frataxin data from OLE and prior studies intended to support BLA for accelerated approval targeted H2 2025.
- Nomlabofusp remains under partial clinical hold; 50 mg cohort data will be submitted to FDA for dose escalation review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000095017024029236/0000950170-24-029236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000095017024029236/lrmr-20240311.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-029236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer